RAPT Therapeutics, Inc.’s RAPT share price has surged by 16.79%, which has investors questioning if this is right time to ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for RAPT Therapeutics in a note issued to investors ...

There is no curative treatment at the moment, although various drugs, including chemotherapy, retinoids, interferons, HDAC inhibitors, and Kyowa Kirin’s anti-CCR4 antibody Poteligeo ...

Tivumecirnon is an oral C-C chemokine receptor 4 (CCR4) antagonist claimed to improve immune activity within the tumour microenvironment. The drug is designed to block the CCR4 receptor protein ...

Th17 cells, identified based on CD4+ CXCR3-CCR4+CCR6+ phenotype,30 were sorted by flow cytometry and further expanded as bulk populations. Th17 clones (hereafter referred to as CRC-Th17) were ...

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Protein synthesis is an essential process, ...